Barcelona patent court finds oxycodone and naloxone patent invalid due to added matter

On 19 December 2018 Barcelona Commercial Court Number 4 dismissed a patent infringement action brought by Mundipharma against two generics of its oxycodone and naloxone medicinal product for the treatment of pain (Targin) and upheld the defendants’ counterclaim that the asserted patent was invalid. Facts Mundipharma holds European Patent EP2425825 (EP’825), entitled ‘Pharmaceutical preparation containing…